Clinical trial
Phase 2 Study to Evaluate the Safety and Efficacy of ARO-ANG3 in Subjects With Homozygous Familial Hypercholesterolemia (HOFH)
NCT05217667 is registered in ClinicalTrials.gov with Arrowhead Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study to Evaluate the Safety and Efficacy of ARO-ANG3 in Subjects With Homozygous Familial Hypercholesterolemia (HOFH)
- Lead sponsor
- Arrowhead Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- April 22, 2022
- Completion date
- November 13, 2025
- Enrollment
- 18 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.